On March 20, the FDA approved nivolumab with doxorubicin, vinblastine, and dacarbazine for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma. For more information, read the FDA announcement and the Bristol Myers Squibb press release.
On March 20, the FDA approved nivolumab with doxorubicin, vinblastine, and dacarbazine for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma.
For more information, read the FDA announcement and the Bristol Myers Squibb press release.
Posted on 3/26/2026
